Advanced

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Hansson, Oskar LU ; Lehmann, Sylvain; Otto, Markus; Zetterberg, Henrik LU and Lewczuk, Piotr (2019) In Alzheimer's Research and Therapy 11(1). p.1-15
Abstract

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of... (More)

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer’s Disease, Amyloidβ Peptides, Aβ42/40 ratio, Biomarkers, Cerebrospinal Fluid
in
Alzheimer's Research and Therapy
volume
11
issue
1
pages
15 pages
publisher
BioMed Central
external identifiers
  • scopus:85064685368
ISSN
1758-9193
DOI
10.1186/s13195-019-0485-0
language
English
LU publication?
yes
id
89a23b2c-c5f5-4aa7-b57c-d55ba7aaa577
date added to LUP
2019-05-03 10:47:44
date last changed
2019-05-28 03:57:20
@article{89a23b2c-c5f5-4aa7-b57c-d55ba7aaa577,
  abstract     = {<p>The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.</p>},
  author       = {Hansson, Oskar and Lehmann, Sylvain and Otto, Markus and Zetterberg, Henrik and Lewczuk, Piotr},
  issn         = {1758-9193},
  keyword      = {Alzheimer’s Disease,Amyloidβ Peptides,Aβ42/40 ratio,Biomarkers,Cerebrospinal Fluid},
  language     = {eng},
  month        = {04},
  number       = {1},
  pages        = {1--15},
  publisher    = {BioMed Central},
  series       = {Alzheimer's Research and Therapy},
  title        = {Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease},
  url          = {http://dx.doi.org/10.1186/s13195-019-0485-0},
  volume       = {11},
  year         = {2019},
}